NIH

The Foundation for the National Institutes of Health Launches First Public-Private Partnership for Early Detection of Preeclampsia

Retrieved on: 
Monday, February 12, 2024

The Foundation for the National Institutes of Health (FNIH) today announces the launch of a new public-private partnership to develop tools to identify pregnant women at high risk of early-onset preeclampsia.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) today announces the launch of a new public-private partnership to develop tools to identify pregnant women at high risk of early-onset preeclampsia.
  • Preeclampsia is a serious pregnancy-related hypertensive disorder that can lead to maternal and neonatal deaths and long-term negative health outcomes.
  • The disorder is becoming more prevalent in the United States, with women of color more likely to be affected and experience poor outcomes.
  • Currently, preeclampsia risk is determined early in pregnancy using a combination of maternal medical history and clinical risk factors.

Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD

Retrieved on: 
Monday, February 12, 2024

CHATHAM, N.J., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Phase 2 investigator-initiated OASIS trial to evaluate TNX-102 SL1 in reducing the severity of acute stress reaction (ASR) and the frequency of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD). The trial is sponsored by The University of North Carolina (UNC) Institute for Trauma Recovery and supported by a $3 million grant from the U.S. Department of Defense (DoD).

Key Points: 
  • “There is an unmet need for treating ASR after traumatic events such as civilian motor vehicle collisions or warfighter experiences in forward bases or in theater.
  • Participants will be randomized in the ED to receive a two-week course of either TNX-102 SL 5.6 mg or placebo.
  • The OASIS trial will build upon a foundation of knowledge and infrastructure developed through the UNC-led, $40 million AURORA initiative.
  • AURORA is a major national research initiative to improve the understanding, prevention, and recovery of individuals who experience a traumatic event.

Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors

Retrieved on: 
Monday, February 12, 2024

DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.

Key Points: 
  • DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024.
  • Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.
  • Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020.
  • "I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors.

Important NIH INCLUDE Legislation Aimed at Increasing Lifespan and Dramatically Improving Health Outcomes for People with Down Syndrome Introduced by GLOBAL Champion, Congresswoman Cathy McMorris Rodgers

Retrieved on: 
Thursday, February 8, 2024

“Working with Congresswoman Cathy McMorris Rodgers has been one of the greatest honors of my life,” says Michelle Sie Whitten, GLOBAL President & CEO.

Key Points: 
  • “Working with Congresswoman Cathy McMorris Rodgers has been one of the greatest honors of my life,” says Michelle Sie Whitten, GLOBAL President & CEO.
  • “With this bill, named in memory of our beloved Ambassador DeOndra Dixon, Congresswoman McMorris Rodgers is helping to create a powerful future for a population that has been largely ignored and neglected.
  • “I remember DeOndra keynoting alongside Congresswoman Cathy McMorris Rodgers and Congressman Patrick Kennedy, and she was cracking everybody up with her jokes.
  • To read about the impactful research that the INCLUDE Project has funded visit the NIH Down Syndrome Coordinating Center Website at: https://includedcc.org/.

Meet Eldie—The Only Gummy on The Market With High Potency, Zero Refined or Artificial Sweeteners, AND American-Grown Organic Elderberries

Retrieved on: 
Thursday, February 8, 2024

Eldie joins the CA-based company’s line of fresh-pressed, American-grown culinary and wellness products, including: immune syrups, preserves, teas, and balsamic vinegars.

Key Points: 
  • Eldie joins the CA-based company’s line of fresh-pressed, American-grown culinary and wellness products, including: immune syrups, preserves, teas, and balsamic vinegars.
  • “While the process of crafting the immune gummy took more than 12 months, I refused to compromise on anything,” said Reneker.
  • “Our Eldies are made using top-notch sourcing; have 3X the amount of American-grown organic elderberries per serving than many leading brands on the market; contain only natural, zero-refined sweeteners; and incorporate more sustainable packaging.
  • An immune gummy you can feel really good about including in your family’s and your own daily wellness routine.”
    Eldie—The Gummy That Checks All The Boxes!

Pacific Dental Services Marks American Heart Month with Expanded Focus on Oral Health Awareness

Retrieved on: 
Wednesday, February 7, 2024

IRVINE, Calif., Feb. 7, 2024 /PRNewswire/ -- Pacific Dental Services® (PDS), a leading dental and medical support organization in the U.S., is recognizing American Heart Month throughout February with several initiatives that highlight the growing link between oral health and heart health.

Key Points: 
  • IRVINE, Calif., Feb. 7, 2024 /PRNewswire/ -- Pacific Dental Services® (PDS), a leading dental and medical support organization in the U.S., is recognizing American Heart Month throughout February with several initiatives that highlight the growing link between oral health and heart health.
  • "During American Heart Month our focus is on raising awareness about the importance of maintaining optimal oral health — a key contributor to improved heart health," said Stephen E. Thorne, Founder and CEO of Pacific Dental Services.
  • PDS-supported clinicians regularly educate patients about the link between oral health and overall health — also known as the Mouth-Body Connection® .
  • Throughout American Heart Month, PDS is conducting several initiatives to increase awareness about the connection between oral health and heart health, such as:
    Participating in National Wear Red Day to show support and raise awareness for heart health.

The Foundation for the National Institutes of Health Announces Publication of Regulatory Playbook to Advance AAV Gene Therapies for Rare Diseases

Retrieved on: 
Tuesday, February 6, 2024

The Foundation for the National Institutes of Health (FNIH) today announces the online publication of the first “playbook” designed to help accelerate the development of adeno-associated virus (AAV) gene therapies for rare diseases.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) today announces the online publication of the first “playbook” designed to help accelerate the development of adeno-associated virus (AAV) gene therapies for rare diseases.
  • AMP BGTC is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), life science companies, and patient foundations.
  • “Gene therapies offer promise to thousands of patients with rare diseases, but progress is slowed by uncertainties about manufacturing and a clear regulatory path.
  • The playbook was created as a “one-stop-shop guide” for clinical and drug development researchers who are working to bring AAV gene therapies to rare disease patients.

Record Year Detailed in ISS National Laboratory® Annual Report

Retrieved on: 
Tuesday, February 6, 2024

These successes and many others are highlighted in the ISS National Lab Annual Report for FY23 released today by the Center for the Advancement of Science in Space™ (CASIS™).

Key Points: 
  • These successes and many others are highlighted in the ISS National Lab Annual Report for FY23 released today by the Center for the Advancement of Science in Space™ (CASIS™).
  • CASIS has served as manager of the ISS National Lab for 12 years through a Cooperative Agreement with NASA.
  • Some highlights of FY23 accomplishments:
    Last year, 113 ISS National Lab-sponsored payloads were delivered to the space station—the most ever in a single fiscal year.
  • This brings the total number of peer-reviewed articles related to ISS National Lab R&D to more than 350.

Parkinson's Foundation to Accelerate Research Through Expanded Genetic Testing and Counseling Study

Retrieved on: 
Tuesday, February 6, 2024

NEW YORK and MIAMI, Feb. 6, 2024 /PRNewswire/ -- Through its Global Parkinson's Genetics Program (GP2), Aligning Science Across Parkinson's (ASAP) has awarded the Parkinson's Foundation a grant that will significantly expand its landmark international genetics study, PD GENEration: Mapping the Future of Parkinson's Disease. The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD). ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.

Key Points: 
  • The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD).
  • ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.
  • It is a patient-facing research study," said Parkinson's Foundation Senior Vice President and Chief Scientific Officer James Beck, PhD.
  • Fox Foundation for Parkinson's Research is ASAP's implementation partner and issued the grants on behalf of ASAP and GP2.

First Patient Enrollment into Aspero Medical NIH-Funded Study

Retrieved on: 
Monday, February 5, 2024

The study will be specific to the middle third of small bowel for balloon enteroscopy and completion is expected by end of 2024.

Key Points: 
  • The study will be specific to the middle third of small bowel for balloon enteroscopy and completion is expected by end of 2024.
  • The first patient of this study was enrolled last week.
  • Unlike the Ancora-SB balloon made by Aspero Medical, current balloons are smooth and round making them prone to slippage.
  • “We are beyond excited to have the first patient enrolled in the NIH-funded RCT.